Press Releases
Enveric Biosciences Receives Notice of Allowance from USPTO for EVM301 Series of Drug Candidates
New composition of matter claims establish intellectual property for Enveric’s EVM301 Series of novel small molecules designed to promote neuroplasticity without inducing hallucinations. CAMBRIDGE, Mass. – Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, […]
Enveric Biosciences Announces Poster Presentation at Canadian Neuroscience Meeting 2023
CAMBRIDGE, Mass. – Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced that research foundational to the development of the Company’s EVM201 Series and EVM301 Series is featured in a poster presentation at […]
Enveric Biosciences Receives Notice of Allowance From USPTO for C4-Carboxylic Acid-Substituted Tryptamine Derivatives for Next Generation Psilocin Prodrug
New composition of matter claims expands intellectual property for Enveric’s EVM201 Series CAMBRIDGE, Mass. – Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced that it has received a Notice of Allowance from […]
Enveric Biosciences Announces Manuscript Detailing the Development of Novel Psilocin Prodrugs for the Treatment of Anxiety and Other Mental Health Disorders
Research highlights the potential of Enveric’s EVM201 Series aimed at developing psilocin prodrugs with altered metabolic profiles that offer superior administration and treatment benefits, but reduce pharmacological exposure CAMBRIDGE, Mass. – Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of […]
Enveric Biosciences to Participate in 2023 BIO International Convention in Boston
CAMBRIDGE, Mass. – Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced its participation in this year’s 2023 BIO International Convention, which is being held in Boston, MA, June 5-8, 2023. During the […]
Enveric Biosciences Receives Notice of Allowance from USPTO for Novel Prodrug of Psilocin
Intellectual property describes composition of matter claims governing Enveric’s lead clinical candidate, EB-373, which is being developed for the treatment of anxiety disorder CAMBRIDGE, Mass. – Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, […]
Enveric Biosciences Reports First Quarter 2023 Financial Results and Operational Highlights
Announced cost reduction plan resulting in approximately 40% to 55% decrease in expenses and extension of financial runway into Q1 2024 Continued to advance pipeline of small molecule therapeutics for the treatment of mental health disorders, including EB-373 for the treatment of anxiety disorder and EVM301 Series Announced termination of proposed spin-off of cannabinoid clinical […]
Enveric Biosciences Celebrates and Supports 2023 Mental Health Awareness Month
Enveric is advancing EB-373, a psilocin prodrug for anxiety disorders and its EVM301 Series of novel non-hallucinatory brain plastogens to treat mental health disorders. CAMBRIDGE, Mass. – Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction […]
Enveric Biosciences to Participate in Benzinga Psychedelics Capital Conference
CEO Joseph Tucker, Ph.D., to discuss Enveric’s pipeline and therapeutic opportunities in fireside chat and “NextGen Psychedelics” panel discussion CAMBRIDGE, Mass. – Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced that Joseph Tucker, […]
Enveric Biosciences Reports Fourth Quarter and Year-End 2022 Corporate and Financial Results
Key Highlights Nominated EB-373 as lead development candidate for the treatment of anxiety disorders EB-373 is a next generation proprietary psilocin prodrug selected from Enveric’s EVM201 Series and developed leveraging the Company’s Psybrary™ drug discovery platform Established Australia-based subsidiary, Enveric Therapeutics Pty. Ltd and identified contract research organization (CRO) Avance Clinical to conduct Phase 1 […]